BRRLY yields 0.95% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 7
Combined, BRRLY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BRRLY + JNJ for your $10,000?
Barry Callebaut AG, together with its subsidiaries, engages in the manufacture and sale of chocolate and cocoa products. The company provides chocolates, compounds, chips and chunks, cocoa, cacao fruit, fillings, coatings, nuts, decorations and inclusions, and food colorants, as well as personalization sheets. It also offers cocoa powder, chocolate drinks, cappuccinos, dessert drinks, dairy and non-dairy products, tea, and coffee. The company provides products under the ASM, Barry Callebaut, Cacao Barry, Callebaut, Carma, Chocovic, Mona Lisa, Gertrude Hawk Ingredients, Van Houten Professional, Bensdorp, Cabosse Naturals, Caprimo, D'Orsogna Dolciaria, IBC, and La Morella Nuts names. In addition, it offers centralized treasury and management services; research and development; insurance; and conference and training services offered through CHOCOLATE ACADEMY centers. The company serves food manufacturers and artisans; and professional users of chocolate, including chocolatiers, pastry chefs, bakers, hotels, restaurants, or caterers. It also offers products for vending machines. The company operates primarily in the United States, Germany, the United Kingdom, Belgium, France, Mexico, Brazil, Poland, Switzerland, rest of Europe, rest of Americas, and the Asia Pacific. Barry Callebaut AG was incorporated in 1996 and is headquartered in Zürich, Switzerland.
Full BRRLY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.